Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

University of Pittsburgh

Overview

This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fidaxomicin

This single site study will be a clinical research data base of patients hospitalized and diagnosed with Clostridium difficile infection (CDI), treated with Fidaxomicin and willing to allow us to collect discard biological samples for testing and analysis in the investigators lab. An additional blood sample will be obtained if a clinically indicated bronchoscopy is performed as to measure the amount of medication in the BAL. We will also complete a medical record review will also occur.

Study Type

OBSERVATIONAL

Conditions

Clostridium Difficile Infection (CDI)

Interventions

FidaxomicinDRUG

patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. ≥18 years of age 2. Currently an inpatient at UPMC Presbyterian 3. Diagnosed with an CDI 4. Being treated with Fidaxomicin Exclusion Criteria: not meeting entry criteria

Locations (1)

UPMC

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

risks factors

Incidence of death as indicated in medical record

Time frame: "1 year"

Secondary Outcomes

CDI episodes

quantified by number of stools in a day as reported in medical record

Time frame: "1 year"

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.